AnaptysBio (ANAB) Projected to Post Earnings on Monday

AnaptysBio (NASDAQ:ANAB - Get Free Report) is expected to be releasing its earnings data before the market opens on Monday, March 10th. Analysts expect AnaptysBio to post earnings of ($1.55) per share and revenue of $7.79 million for the quarter.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.61) by $0.89. The company had revenue of $43.11 million during the quarter, compared to analysts' expectations of $10.17 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. On average, analysts expect AnaptysBio to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

AnaptysBio Stock Performance

NASDAQ:ANAB traded down $0.35 during trading hours on Thursday, reaching $16.40. The company's stock had a trading volume of 782,798 shares, compared to its average volume of 1,059,337. The firm has a market capitalization of $499.04 million and a price-to-earnings ratio of -2.70. The firm has a 50-day simple moving average of $16.16 and a 200-day simple moving average of $24.22. AnaptysBio has a 1 year low of $12.21 and a 1 year high of $41.31.

Insider Activity at AnaptysBio

In other news, Director Ecor1 Capital, Llc purchased 6,646 shares of the stock in a transaction dated Thursday, January 2nd. The shares were acquired at an average cost of $12.95 per share, for a total transaction of $86,065.70. Following the acquisition, the director now owns 7,880,094 shares of the company's stock, valued at approximately $102,047,217.30. This represents a 0.08 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 33.70% of the stock is currently owned by company insiders.

Remove Ads

Analysts Set New Price Targets

Several research analysts have recently commented on the company. JPMorgan Chase & Co. lifted their price objective on AnaptysBio from $36.00 to $42.00 and gave the stock an "overweight" rating in a report on Wednesday. Truist Financial decreased their price target on AnaptysBio from $30.00 to $20.00 and set a "hold" rating on the stock in a research note on Wednesday, December 18th. Wells Fargo & Company increased their price objective on AnaptysBio from $40.00 to $51.00 and gave the company an "overweight" rating in a research note on Thursday, February 13th. Guggenheim cut their target price on shares of AnaptysBio from $90.00 to $36.00 and set a "buy" rating on the stock in a report on Thursday, December 12th. Finally, Wolfe Research began coverage on shares of AnaptysBio in a report on Tuesday, February 4th. They set an "outperform" rating and a $25.00 price target for the company. Four investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $35.11.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.